医学
结扎
剪裁(形态学)
止血
外科
憩室炎
荟萃分析
内科学
语言学
哲学
作者
Naoyoshi Nagata,Ryota Niikura,Naoki Ishii,Mitsuru Kaise,Fumio Omata,Naoyuki Tominaga,Tomoyuki Kitagawa,Takashi Ikeya,Katsumasa Kobayashi,Yohei Furumoto,Toshiaki Narasaka,Eri Iwata,Mitsushige Sugimoto,Takao Itoi,Naomi Uemura,Takashi Kawai
摘要
Abstract Background and Aim Either clipping or band ligation will become the most common endoscopic treatment for colonic diverticular bleeding (CDB). Rebleeding is a significant clinical outcome of CDB, but there is no cumulative evidence comparing reduction of short‐term and long‐term rebleeding between them. Thus, we conducted a systematic review and meta‐analysis to determine which endoscopic treatment is more effective to reduce recurrence of CDB. Methods A comprehensive search of the databases PubMed/MEDLINE and Embase was performed through December 2019. Main outcomes were early and late rebleeding rates, defined as bleeding within 30 days and 1 year of endoscopic therapy for CDB. Initial hemostasis, need for transcatheter arterial embolization, or surgery were also assessed. Overall pooled estimates were calculated. Results Sixteen studies fulfilled the eligibility criteria, and a total of 790 participants were included. The pooled prevalence of early rebleeding was significantly lower for band ligation than clipping (0.08 vs 0.19; heterogeneity test, P = 0.012). The pooled prevalence of late rebleeding was significantly lower for band ligation than clipping (0.09 vs 0.29; heterogeneity test, P = 0.024). No significant difference of initial hemostasis rate was noted between the two groups. Pooled prevalence of need for transcatheter arterial embolization or surgery was significantly lower for band ligation than clipping (0.01 vs 0.02; heterogeneity test, P = 0.031). There were two cases with colonic diverticulitis due to band ligation but none in clipping. Conclusion Band ligation therapy was more effective compared with clipping to reduce recurrence of colonic diverticular hemorrhage over short‐term and long‐term durations.
科研通智能强力驱动
Strongly Powered by AbleSci AI